Is Rocket Lab Stock a Buy After the SpaceX IPO?

Rocket Lab is down 6.6% since SpaceX’s IPO, even as revenue continues to grow rapidly and EBITDA losses narrow. TTM revenue was $679.6 million, EBITDA was negative $140.1 million, and cash on hand was $1 billion, while the stock trades at about 100x sales versus SpaceX at roughly 130x. The key catalyst is Neutron, which could open heavier-payload contracts and allow Rocket Lab to compete more directly with SpaceX if it launches on schedule before year-end.

Analysis

The market is still treating this as a sentiment trade, but the real issue is customer-access optionality. Rocket Lab’s current mix is constrained by small-payload demand, which caps pricing power and keeps utilization lumpy; Neutron matters less as a rocket than as a sales unlock for a broader addressable budget pool. If the vehicle reaches orbit credibly, the second-order effect is a re-rating of contract size and backlog quality, not just launch cadence.

The valuation debate is more nuanced than “expensive versus more expensive.” A high sales multiple can be defensible when the incremental TAM expansion is near-term and visible; here, the asymmetry is that SpaceX is already monetizing the core heavy-lift market while Rocket Lab is still trying to prove it can enter it. That means RKLB’s multiple can compress hard on any further delay, because the equity is pricing a successful transition before the company has de-risked execution.

The main catalyst path is binary over the next 3-9 months: a clean Neutron milestone likely triggers multiple expansion and improved contract quality, while another slip keeps the stock hostage to speculative positioning. The contrarian miss is that the post-SpaceX pop may have shifted attention toward the entire category just as the weaker name remains the cleaner way to express the launch beta — but only if one accepts higher technical and schedule risk. In other words, the setup is better for event-driven traders than for long-only holders.

Relative winners outside the article are launch-adjacent suppliers and defense-space primes that can absorb demand if Neutron slips; they get the benefit of delayed competitive pressure without needing perfect execution. The loser is any customer segment that was waiting for a lower-cost, medium-lift alternative and may continue paying up for existing providers longer than the market expects.

Key Decisions for Investors

• Avoid chasing RKLB outright at current levels; wait for a post-catalyst setup or a pullback tied to schedule skepticism. Risk/reward remains poor until Neutron de-risks, because downside from another delay likely exceeds 20-30% while upside before proof is limited.
• For event-driven exposure, consider a small long RKLB Jan-2026 call spread financed with a higher strike call sale. This captures a successful Neutron/orbit milestone while capping premium burn if timelines slip again.
• Pair trade: long RKLB / short a basket of overvalued space-adjacent names only if you can isolate idiosyncratic catalyst risk; otherwise prefer long defense-space suppliers over RKLB for lower execution risk and cleaner cash-flow support over the next 6-12 months.
• Set a trigger to add only on a successful Neutron launch or a credible new contract announcement tied to medium/heavy-lift payloads. That is the point where revenue quality, not just revenue growth, starts to improve.
• If you want to express skepticism, use put spreads on RKLB into the next major launch window rather than outright shorts. The stock’s sentiment sensitivity makes downside moves sharp, but borrow and squeeze risk are high.